Umut Kalyoncu1, Özün Bayindir2, Mustafa Ferhat Öksüz3, Atalay Doğru4, Gezmiş Kimyon5, Emine Figen Tarhan6, Abdulsamet Erden7, Şule Yavuz8, Meryem Can9, Gözde Yıldırım Çetin10, Levent Kılıç11, Orhan Küçükşahin12, Ahmet Omma13, Cem Ozisler14, Dilek Solmaz15, Emine Duygu Ersözlü Bozkirli16, Lütfi Akyol17, Seval Masatlıoğlu Pehlevan18, Esen Kasapoglu Gunal19, Fatos Arslan19, Barış Yılmazer20, Nilgun Atakan21, Sibel Zehra Aydın22. 1. Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara umut.kalyoncu@yahoo.com. 2. Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ege University, Izmir. 3. Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Uludag University, Bursa. 4. Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Suleyman Demirel University, Isparta. 5. Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Gaziantep University, Ankara. 6. Department of Internal Medicine, Division of Rheumatology, Izmir Katip Celebi University School of Medicine, Izmir. 7. Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara. 8. Istanbul Florence Nightingale Hospital, Department of Rheumatology, Istanbul Bilim University. 9. Department of Rheumatology, Fatih Sultan Mehmet Education and Research Hospital, İstanbul. 10. Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Sutcu Imam University, Kahramanmaras. 11. Department of Rheumatology, Yildirim Beyazit University, Yenimahalle Education and Research Hospital, Ankara. 12. Faculty of Medicine, Atatürk Education and Research Hospital Department of Rheumatology, Yıldırım Beyazit University. 13. Department of Rheumatology, Ankara Numune Training and Research Hospital. 14. Department of Rheumatology, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara. 15. Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Namik Kemal University, Tekirdag. 16. Division of Rheumatology, Adana Numune Training and Research Hospital, Adana. 17. Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ondokuz Mayıs University, Samsun. 18. Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Fatih University. 19. Istanbul Medeniyet University, Goztepe Training and Research Hospital. 20. Department of Rheumatology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, İstanbul. 21. Faculty of Medicine, Department of Dermatology, Hacettepe University, Ankara, Turkey. 22. Division of Rheumatology, University of Ottawa, Ottawa, Ontario, Canada.
Abstract
OBJECTIVE: The aim was to assess the characteristics of PsA, find out how well the disease is controlled in real life, demonstrate the treatments and identify the unmet needs. METHODS: The PsA registry of Turkey is a multicentre Web-based registry established in 2014 and including 32 rheumatology centres. Detailed data regarding demographics for skin and joint disease, disease activity assessments and treatment choices were collected. RESULTS: One thousand and eighty-one patients (64.7% women) with a mean (sd) PsA duration of 5.8 (6.7) years were enrolled. The most frequent type of PsA was polyarticular [437 (40.5%)], followed by oligoarticular [407 (37.7%)] and axial disease [372 (34.4%)]. The mean (sd) swollen and tender joint counts were 1.7 (3) and 3.6 (4.8), respectively. Of these patients, 38.6% were on conventional synthetic DMARD monotherapy, 7.1% were on anti-TNF monotherapy, and 22.5% were using anti-TNF plus conventional synthetic DMARD combinations. According to DAS28, 86 (12.4%) patients had high and 105 (15.2%) had moderate disease activity. Low disease activity was achieved in 317 (45.7%) patients, and 185 (26.7%) were in remission. Minimal disease activity data could be calculated in 247 patients, 105 of whom (42.5%) had minimal disease activity. The major differences among sexes were that women were older and had less frequent axial disease, more fatigue, higher HAQ scores and less remission. CONCLUSION: The PsA registry of Turkey had similarities with previously published registries, supporting its external validity. The finding that women had more fatigue and worse functioning as well as the high percentage of active disease state highlight the unmet need in treatment of PsA.
OBJECTIVE: The aim was to assess the characteristics of PsA, find out how well the disease is controlled in real life, demonstrate the treatments and identify the unmet needs. METHODS: The PsA registry of Turkey is a multicentre Web-based registry established in 2014 and including 32 rheumatology centres. Detailed data regarding demographics for skin and joint disease, disease activity assessments and treatment choices were collected. RESULTS: One thousand and eighty-one patients (64.7% women) with a mean (sd) PsA duration of 5.8 (6.7) years were enrolled. The most frequent type of PsA was polyarticular [437 (40.5%)], followed by oligoarticular [407 (37.7%)] and axial disease [372 (34.4%)]. The mean (sd) swollen and tender joint counts were 1.7 (3) and 3.6 (4.8), respectively. Of these patients, 38.6% were on conventional synthetic DMARD monotherapy, 7.1% were on anti-TNF monotherapy, and 22.5% were using anti-TNF plus conventional synthetic DMARD combinations. According to DAS28, 86 (12.4%) patients had high and 105 (15.2%) had moderate disease activity. Low disease activity was achieved in 317 (45.7%) patients, and 185 (26.7%) were in remission. Minimal disease activity data could be calculated in 247 patients, 105 of whom (42.5%) had minimal disease activity. The major differences among sexes were that women were older and had less frequent axial disease, more fatigue, higher HAQ scores and less remission. CONCLUSION: The PsA registry of Turkey had similarities with previously published registries, supporting its external validity. The finding that women had more fatigue and worse functioning as well as the high percentage of active disease state highlight the unmet need in treatment of PsA.
Authors: Laure Gossec; Xenofon Baraliakos; Andreas Kerschbaumer; Maarten de Wit; Iain McInnes; Maxime Dougados; Jette Primdahl; Dennis G McGonagle; Daniel Aletaha; Andra Balanescu; Peter V Balint; Heidi Bertheussen; Wolf-Henning Boehncke; Gerd R Burmester; Juan D Canete; Nemanja S Damjanov; Tue Wenzel Kragstrup; Tore K Kvien; Robert B M Landewé; Rik Jozef Urbain Lories; Helena Marzo-Ortega; Denis Poddubnyy; Santiago Andres Rodrigues Manica; Georg Schett; Douglas J Veale; Filip E Van den Bosch; Désirée van der Heijde; Josef S Smolen Journal: Ann Rheum Dis Date: 2020-06 Impact factor: 27.973